Echinacea for Respiratory Health

Research suggests that Echinacea, particularly Echinacea purpurea extracts, may have antiviral properties relevant to respiratory health, with laboratory studies indicating the ability to inhibit SARS-CoV-2 variants and reduce viral replication in cell cultures, though one comparative study found Echinacea performed less strongly than St. John's Wort under similar conditions. The available evidence comes primarily from in vitro studies, computational modeling, and broad reviews of medicinal plant use — with no randomized controlled trials or clinical studies included in this body of research — meaning findings cannot yet be directly translated to human outcomes. Broader reviews of plant-based respiratory treatments situate Echinacea within a wider landscape of botanicals showing preclinical promise, while consistently noting that much of the underlying evidence stems from traditional use or laboratory settings rather than rigorous human trials. Studies indicate that while the mechanistic rationale for Echinacea's antiviral effects is being actively explored, significant research gaps remain, and no conclusions about clinical efficacy or therapeutic benefit in people can be drawn from the current evidence.